Article Dans Une Revue Asian Journal of Cardiology Research Année : 2025

A Case Report of Severe Hypovolemic Hyponatremia Secondary to Angiotensin Receptor Blocker- thiazide Diuretic Usage

Résumé

Key Clinical Message: Telmisartan-hydrochlorthiazide is a US FDA and CDSCO approved oral Fixed Dose combination of ARB & Diuretic for treating hypertension as second line therapy. Telmisartan is an ARBs prevent angiotensin II acting on AT1 receptors and are similar to ACEIs, but have no effect on bradykinin and do not cause cough or bradykinin-related anaphylaxis. We describe a case report of 59-Year-old female who developed severe hyponatremia following the recent administration of Telmisartan-hydrochlorthiazide Combination. Clinical and laboratory evaluations suggest severe Hypovolemic Hyponatremia, likely secondary to Angiotensin receptor blocker-thiazide diuretic. The potential side effects of this Fixed Dose Combination medication requires regular monitoring, patient education.

Fichier non déposé

Dates et versions

hal-05234517 , version 1 (02-09-2025)

Identifiants

  • HAL Id : hal-05234517 , version 1

Citer

Mohammed Ziauddin, Mohammed Zabeer Uddin, Ummay Mariya, Tarannum Fatima. A Case Report of Severe Hypovolemic Hyponatremia Secondary to Angiotensin Receptor Blocker- thiazide Diuretic Usage. Asian Journal of Cardiology Research, 2025, 8 (1), pp.533-537. ⟨hal-05234517⟩
42 Consultations
0 Téléchargements

Partager

  • More